Llorca C - Search Results

1

Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer.

Aparicio J, Vicent JM, Maestu I, Garcerá S, Busquier I, Bosch C, Llorca C, Díaz R, Fernández-Martos C, Galán A. Aparicio J, et al. Among authors: llorca c. Ann Oncol. 2003 Jul;14(7):1121-5. doi: 10.1093/annonc/mdg285. Ann Oncol. 2003. PMID: 12853356 Free article. Clinical Trial.

2

Extragonadal nongestational choriocarcinoma involving the lung: a report of three cases.

Aparicio J, Oltra A, Martínez-Moragón E, Llorca C, Gómez-Aldaraví L, Pastor M. Aparicio J, et al. Among authors: llorca c. Respiration. 1996;63(4):251-3. doi: 10.1159/000196555. Respiration. 1996. PMID: 8815974

3

Randomised comparison of ceftazidime and imipenem as initial monotherapy for febrile episodes in neutropenic cancer patients.

Aparicio J, Oltra A, Llorca C, Montalar J, Herranz C, Gómez-Codina J, Pastor M, Munárriz B. Aparicio J, et al. Among authors: llorca c. Eur J Cancer. 1996 Sep;32A(10):1739-43. doi: 10.1016/0959-8049(96)00188-8. Eur J Cancer. 1996. PMID: 8983283 Clinical Trial.

4

Multicenter phase I study of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer.

Aparicio J, de las Peñas R, Vicent JM, Garcerá S, Llorca C, Maestu I, Yuste AL, Farrés J. Aparicio J, et al. Among authors: llorca c. Oncology. 2002;63(1):42-7. doi: 10.1159/000065719. Oncology. 2002. PMID: 12187070 Clinical Trial.

5

Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study.

Morales S, Lorenzo A, Ramos M, Ballesteros P, Méndez M, Almanza C, Castellanos J, Moreno-Nogueira JA, Casal J, Lizón J, Oltra A, Frau A, Machengs I, Galán A, Belón J, Llorca C. Morales S, et al. Among authors: llorca c. Cancer Chemother Pharmacol. 2004 Jan;53(1):75-81. doi: 10.1007/s00280-003-0690-0. Epub 2003 Oct 14. Cancer Chemother Pharmacol. 2004. PMID: 14557896 Clinical Trial.

6

Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer.

Maestu I, Gómez-Aldaraví L, Torregrosa MD, Camps C, Llorca C, Bosch C, Gómez J, Giner V, Oltra A, Albert A. Maestu I, et al. Among authors: llorca c. Lung Cancer. 2003 Dec;42(3):345-54. doi: 10.1016/s0169-5002(03)00356-8. Lung Cancer. 2003. PMID: 14644523 Clinical Trial.

7

First-line treatment with irinotecan and raltitrexed in metastatic colorectal cancer. Mature results of a multicenter phase II study.

Aparicio J, Vicent JM, Maestu I, Bosch C, Galán A, Busquier I, Llorca C, Garcerá S, Campos JM, López-Tendero P, Balcells M. Aparicio J, et al. Among authors: llorca c. Oncology. 2005;68(1):58-63. doi: 10.1159/000084821. Epub 2005 Mar 8. Oncology. 2005. PMID: 15809521 Clinical Trial.

8

Pet and common sense: a good choice.

Esquerdo G, Briceño HC, Orts D, Llorca C, Cervera JM, Galán A. Esquerdo G, et al. Among authors: llorca c. J Neurooncol. 2005 Aug;74(1):41. doi: 10.1007/s11060-005-0604-6. J Neurooncol. 2005. PMID: 16078105 No abstract available.

9

FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer.

Aparicio J, Fernandez-Martos C, Vincent JM, Maestu I, Llorca C, Busquier I, Campos JM, Perez-Enguix D, Balcells M. Aparicio J, et al. Among authors: llorca c. Clin Colorectal Cancer. 2005 Nov;5(4):263-7. doi: 10.3816/ccc.2005.n.037. Clin Colorectal Cancer. 2005. PMID: 16356303 Clinical Trial.

10

Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study.

Manso L, Palomo AG, Pérez Carrión R, Cassinello J, Gallegos Sancho I, Chacón López-Muñiz I, Olier C, Fernández-Aramburo A, Llorca C, González X, Llorente R, Torregrosa D, Álvarez I, Gálve E, Bueno C, Garau I, García MJ, González-Santiago S, Ballesteros AI, Blanco E, Galán A, González S, Perelló A, Cortés-Funes H, Grávalos C. Manso L, et al. Among authors: llorca c. Anticancer Res. 2015 Dec;35(12):6941-50. Anticancer Res. 2015. PMID: 26637920

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

27 results

Search Page

Filters